Clinical Trial Search

Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)

Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001

Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001

Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98

Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 74; 22 Participants

Primary: Change From Baseline in Papule/Pustule Count at Week 16 — -5.00 papules and pustules — p=0.01

Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032

Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change

Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 79; 25 Participants

Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale

Primary: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40 — 23.0; 22.5 Lesions

Primary: IGA of Improvement — 3.1; 3.5 units on a scale

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 50.1; 25.9 Percentage of Participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants

Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale

Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction

Primary: Responder — 16.7 percentage of responders

Primary: Investigator Global Assessment (IGA) Score — 0; 0; 20; 0 Participants

Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…

Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants

Primary: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) — 13.3; 20.5…

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 18.38; 14.53 Lesions — p=<0.0001

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 17.56; 15.34 Lesions — p=0.0031

Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale

Primary: Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. — 17; 10; 7; 4…

Primary: Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA): — 53; 35…

Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001

Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions